ClinicalTrials.gg
CompletedNCT01159262Updated Aug 13, 2015Results posted

Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age

A Phase 2/3 interventional study of Midazolam and Fentanyl/Morphine in Sedation, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Completed at 18 sites in 2 countries. Open to participants aged 28 Weeks to 44 Weeks. Per ClinicalTrials.gov, last updated 2015-08-13.

Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
28 Weeks to 44 Weeks
Sex
All
01

Study summary

The purpose of this study is to investigate the safety, efficacy and pharmacokinetics (PK) of dexmedetomidine (DEX) at 3 different dose levels in infants, ages ≥28 weeks to ≤44 weeks gestational age, administered as a loading dose followed by a continuous infusion for a minimum of 6 hours and up to 24 hours in the neonatal intensive care unit (NICU), cardiac intensive care unit (CICU), or pediatric intensive care unit (PICU).

02

Conditions studied

  • Sedation

Keywords

  • Initially intubated and mechanically ventilated neonates
03

In context

Lead sponsor

Hospira, now a wholly owned subsidiary of Pfizer is the lead sponsor of 28 studies on the registry; none are open to participants now.

First submitted before Hospira became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Weeks to 44 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Initially intubated and mechanically ventilated pediatric subjects in an intensive care setting anticipated to require a minimum of 6 hours of continuous IV sedation.
  2. The ability to complete all PK sampling blood draws.
  3. Age: subjects must fit into 1 of the following age ranges at screening:

    • Preterm neonates ≥28 weeks through \<36 weeks, gestational age; this would constitute treatment Group I.
    • Term neonates born at ≥36 weeks through ≤44 weeks gestational age; this would constitute treatment Group II.
  4. Weight: subject's weight at the time of enrollment must be >1000 g.
  5. Subject's parent(s) or legal guardian(s) has/have voluntarily signed and dated the document approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).

Exclusion criteria

Exclusion Criteria:

  1. Neonate subjects with neurological conditions that prohibit an evaluation of sedation such as:

    • Diminished consciousness from increased intracranial pressure.
    • The presence of catastrophic brain injury or other severe mental disorders that would make responses to sedatives unpredictable and/or measurement of the N-PASS unreliable.
    • Subjects with immobility from neuromuscular disease or continuous infusion of neuromuscular blocking (NMB) agents.
  2. Subjects with second degree or third degree heart block unless subject has a pacemaker or pacing wires are in situ.
  3. Heart rate \<120 bpm prior to the initiation of study drug.
  4. Exposure to any drug within 30 days prior to study drug administration.
  5. Previous exposure to Dexmedetomidine (DEX) as part of an investigational study.
  6. Maternal history of poly-substance drug abuse, based upon the presence of 1) an abnormal urine drug screen for cocaine, opiates and/or benzodiazepines; or 2) Investigator's judgment.
  7. At the discretion of the Investigator, subjects in whom the risk of DEX treatment is expected to exceed its benefits.
  8. Subjects who have a known allergy or to fentanyl, morphine, Midazolam, DEX, or other α-2 agonists.
  9. Requirement for medications other than DEX, Midazolam, morphine, or fentanyl for sedation and pain control.
  10. Screening (ALT) levels >115 U/L.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Dexmedetomidine 0.05 mcg/kg

    Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.

    Drug: Midazolam · Drug: Fentanyl/Morphine · Drug: Dexmedetomidine

  • Experimental
    Dexmedetomidine 0.1 mcg/kg

    Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.

    Drug: Midazolam · Drug: Fentanyl/Morphine · Drug: Dexmedetomidine

  • Experimental
    Dexmedetomidine 0.2 mcg/kg

    Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.

    Drug: Midazolam · Drug: Fentanyl/Morphine · Drug: Dexmedetomidine

Interventions

  • Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion

  • DrugFentanyl/Morphine

    Drug pages: Fentanyl · Morphine

    Per package insert, N-PASS scores and investigator discretion.

  • Also known as: Precedex

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Who Received Rescue Medication Midazolam for Sedation During Dexmedetomidine Infusion

    Time frame: During study drug administration (6 to 24 hours)

Secondary outcomes

  1. Percentage of Subjects Who Received Rescue Medication for Analgesia During Dexmedetomidine Infusion

    Time frame: During Study drug administration (6 to 24 hours)

  2. Total Amount of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used)

    Time frame: During Study drug administration (6 to 24 hours)

  3. Total Amount of Rescue Medication Fentanyl Given for Sedation During Dexmedetomidine Infusion (Among Who Used)

    Time frame: During study drug administration (6 to 24 hours)

  4. Total Amount of Rescue Medication Morphine Given for Sedation During Dexmedetomidine Infusion (Among Who Used)

    Time frame: During study drug administration (6 to 24 hours)

  5. Weight-adjusted Total Amount (Per kg) of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used)

    Time frame: During study drug administration (6 to 24 hours)

  6. Weight-adjusted Total Amount (Per kg) of Rescue Medication Fentanyl Given for Analgesia During Dexmedetomidine Infusion (Among Who Used)

    Time frame: During study drug administration (6 to 24 hours)

  7. Weight-adjusted Total Amount (Per kg) of Rescue Medication Morphine Given for Analgesia During Dexmedetomidine Infusion (Among Who Used)

    Time frame: During study drug administration (6 to 24 hours)

  8. Time to Successful Extubation in DEX-exposed Subjects

    Time frame: From start of DEX administration to extubation of each subject up to 7 days post-infusion

07

Results

Posted Dec 12, 2014

Participant flow

Participant flow — Overall Study
MilestoneDexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kg
Started14148
Completed14148
Not completed000

Outcome measures

PrimaryPercentage of Subjects Who Received Rescue Medication Midazolam for Sedation During Dexmedetomidine Infusion
Time frame:
During study drug administration (6 to 24 hours)
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Received Rescue Medication Midazolam for Sedation During Dexmedetomidine Infusion
percentage of subjectsDexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kg
Percentage of Subjects Who Received Rescue Medication Midazolam for Sedation During Dexmedetomidine Infusion7.17.125
SecondaryPercentage of Subjects Who Received Rescue Medication for Analgesia During Dexmedetomidine Infusion
Time frame:
During Study drug administration (6 to 24 hours)
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Received Rescue Medication for Analgesia During Dexmedetomidine Infusion
percentage of subjectsDexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kg
Percentage of Subjects Who Received Rescue Medication for Analgesia During Dexmedetomidine Infusion35.735.775
SecondaryTotal Amount of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used)
Time frame:
During Study drug administration (6 to 24 hours)
Reported as:
Mean · Milligram
Total Amount of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used)
MilligramDexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kg
Total Amount of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used).360 ± NA.500 ± NA1.125 ± 1.4637
SecondaryTotal Amount of Rescue Medication Fentanyl Given for Sedation During Dexmedetomidine Infusion (Among Who Used)
Time frame:
During study drug administration (6 to 24 hours)
Reported as:
Mean · Microgram
Total Amount of Rescue Medication Fentanyl Given for Sedation During Dexmedetomidine Infusion (Among Who Used)
MicrogramDexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kg
Total Amount of Rescue Medication Fentanyl Given for Sedation During Dexmedetomidine Infusion (Among Who Used)10.808 ± 7.13055.667 ± 3.51199.522 ± 7.5131
SecondaryTotal Amount of Rescue Medication Morphine Given for Sedation During Dexmedetomidine Infusion (Among Who Used)
Time frame:
During study drug administration (6 to 24 hours)
Reported as:
Mean · milligram
Total Amount of Rescue Medication Morphine Given for Sedation During Dexmedetomidine Infusion (Among Who Used)
milligramDexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kg
Total Amount of Rescue Medication Morphine Given for Sedation During Dexmedetomidine Infusion (Among Who Used)—0.275 ± 0.03540.400 ± 0.1732
SecondaryWeight-adjusted Total Amount (Per kg) of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used)
Time frame:
During study drug administration (6 to 24 hours)
Reported as:
Mean · milligrams/Kg
Weight-adjusted Total Amount (Per kg) of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used)
milligrams/KgDexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kg
Weight-adjusted Total Amount (Per kg) of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used)0.100 ± NA0.152 ± NA0.318 ± 0.4133
SecondaryWeight-adjusted Total Amount (Per kg) of Rescue Medication Fentanyl Given for Analgesia During Dexmedetomidine Infusion (Among Who Used)
Time frame:
During study drug administration (6 to 24 hours)
Reported as:
Mean · microgram/Kg
Weight-adjusted Total Amount (Per kg) of Rescue Medication Fentanyl Given for Analgesia During Dexmedetomidine Infusion (Among Who Used)
microgram/KgDexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kg
Weight-adjusted Total Amount (Per kg) of Rescue Medication Fentanyl Given for Analgesia During Dexmedetomidine Infusion (Among Who Used)5.137 ± 6.36961.863 ± 0.87612.725 ± 2.1383
SecondaryWeight-adjusted Total Amount (Per kg) of Rescue Medication Morphine Given for Analgesia During Dexmedetomidine Infusion (Among Who Used)
Time frame:
During study drug administration (6 to 24 hours)
Reported as:
Mean · milligram/Kg
Weight-adjusted Total Amount (Per kg) of Rescue Medication Morphine Given for Analgesia During Dexmedetomidine Infusion (Among Who Used)
milligram/KgDexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kg
Weight-adjusted Total Amount (Per kg) of Rescue Medication Morphine Given for Analgesia During Dexmedetomidine Infusion (Among Who Used)—0.125 ± 0.03480.109 ± 0.0540
SecondaryTime to Successful Extubation in DEX-exposed Subjects
Time frame:
From start of DEX administration to extubation of each subject up to 7 days post-infusion
Reported as:
Median · hour
Time to Successful Extubation in DEX-exposed Subjects
hourDexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kg
Time to Successful Extubation in DEX-exposed Subjects22.9 (4.467 to 100.67)49.3 (33.167 to 79.583)23.7 (4.667 to 67.333)

Adverse events

Collected over Start of study drug administration until 7 days following the start of study drug. Serious adverse events collected from signing of informed consent until 7 days following start of study drug administration or hospital discharge (whichever comes first).. Non-serious events are listed at a 2.8% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dexmedetomidine 0.05 mcg/kg—0/14 (0%)7/14 (50%)
Dexmedetomidine 0.1 mcg/kg—1/14 (7.1%)9/14 (64.3%)
Dexmedetomidine 0.2 mcg/kg—0/8 (0%)6/8 (75%)
Most frequent serious events
Most frequent serious events
EventDexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kg
BradycardiaCardiac disorders0/141/140/8
Cardio-respiratory arrestCardiac disorders0/141/140/8
Oxygen saturation decreasedInvestigations0/141/140/8
Most frequent other events
Showing 10 of 31
Most frequent other events
EventDexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kg
HypokalaemiaMetabolism and nutrition disorders0/140/143/8
AngerPsychiatric disorders0/143/143/8
Plueral effusionRespiratory, thoracic and mediastinal disorders0/140/142/8
HypoalbuminaemiaMetabolism and nutrition disorders0/143/140/8
Blood potassium decreasedInvestigations2/140/140/8
Shunt stenosisInjury, poisoning and procedural complications0/140/141/8
Hemoglobin decreasedInvestigations0/140/141/8
Fluid retentionMetabolism and nutrition disorders0/140/141/8
AtelectasisRespiratory, thoracic and mediastinal disorders1/140/141/8
Pulmonary edemaRespiratory, thoracic and mediastinal disorders0/140/141/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Dexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kgTotal
<=18 years1414836
Between 18 and 65 years0000
>=65 years0000
Age, Continuous
Age, Continuous(weeks)Dexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kgTotal
Mean1.637 ± 1.82901.098 ± 1.08492.225 ± 1.57791.558 ± 1.5382
Age, Customized
Age, Customized(Participants)Dexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kgTotal
= 28 weeks to < 36 weeks gestational age66012
>= 36 weeks to <= 44 weeks gestational age88824
Sex: Female, Male
Sex: Female, Male(Participants)Dexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kgTotal
Female66012
Male88824
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kgTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0101
White1010626
More than one race1001
Unknown or Not Reported3328
Region of Enrollment
Region of Enrollment(participants)Dexmedetomidine 0.05 mcg/kgDexmedetomidine 0.1 mcg/kgDexmedetomidine 0.2 mcg/kgTotal
United States1414836
08

Study locations

18 sites
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Miller Children's Hospital
    Long Beach, California 90806, United States
  • Childrens Hospital Los Angeles
    Los Angeles, California 90027, United States
  • University of California San Francisco, Department of Pediatrics, Division of Neonatology
    San Francisco, California 94143-0734, United States
  • Dept. of Anesthesia, SUMC
    Stanford, California 94305, United States
  • University of Miami - Miller School of Medicine, Department of Anesthesiology
    Miami, Florida 33136, United States
  • Georgia Health Sciences University
    Augusta, Georgia 30912, United States
  • Kapiolani Medical Center for Women and Children
    Honolulu, Hawaii 96826, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Wichita, Kansas 67214, United States
  • Kosair Charities Pediatric Clinical Research Unit, University of Louisville
    Louisville, Kentucky 40202, United States
  • Duke University Medical Center, Department of Anesthesiology
    Durham, North Carolina 27710, United States
  • Akron Children's Hospital Medical Center
    Akron, Ohio 44308, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
  • Greenville, South Carolina 29605, United States
  • West Virginia University School of Medicine
    Morgantown, West Virginia 26506, United States
  • Zona 11 Guatemala, C.P. 01011, Guatemala
09

References and documents

Publications

  • Chrysostomou C, Schulman SR, Herrera Castellanos M, Cofer BE, Mitra S, da Rocha MG, Wisemandle WA, Gramlich L. A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. J Pediatr. 2014 Feb;164(2):276-82.e1-3. doi: 10.1016/j.jpeds.2013.10.002. Epub 2013 Nov 14. PubMed 24238862 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 3 years 4 months after primary completion. A results delay was requested in Sep 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2010
First posted
Jul 9, 2010
Start
Jul 2010
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results delay requested
Sep 12, 2012
Results first posted
Dec 12, 2014
Last update
Aug 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01159262
Responsible party
Sponsor
First posted
Jul 9, 2010
Start date
Jul 2010
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Dec 12, 2014
Last update
Aug 13, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion